Arlen, Philip M <br/><br/>
A randomized phase II study of concurrent docetaxel plus vaccine versus vaccine alone in metastatic androgen-independent prostate cancer.  [electronic resource] 

 -  Clinical cancer research : an official journal of the American Association for Cancer Research  Feb 2006 
 - 1260-9 p.  digital 
<br/><br/> Publication Type: Clinical Trial, Phase II; Journal Article; Randomized Controlled Trial; Research Support, N.I.H., Intramural 
<br/><br/><label>ISSN: </label>1078-0432 
<br/><br/><label>Standard No.: </label>10.1158/1078-0432.CCR-05-2059  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Acid Phosphatase--blood<br/>Aged<br/>Aged, 80 and over<br/>Androgens--physiology<br/>Antigens--blood<br/>Antigens, Neoplasm<br/>Antigens, Surface--blood<br/>Antineoplastic Agents, Phytogenic--therapeutic use<br/>Cancer Vaccines--immunology<br/>Combined Modality Therapy<br/>Cross-Over Studies<br/>Disease-Free Survival<br/>Docetaxel<br/>Glutamate Carboxypeptidase II--blood<br/>Glycoproteins--blood<br/>Humans<br/>Leukocytes, Mononuclear--drug effects<br/>Male<br/>Middle Aged<br/>Mucin-1<br/>Mucins--blood<br/>Neoplasm Metastasis<br/>Prostate-Specific Antigen--blood<br/>Prostatic Neoplasms--drug therapy<br/>Taxoids--therapeutic use<br/>Time Factors<br/>Treatment Outcome<br/>Vaccination--methods